Dialysis Drug Reimbursement Should Be Based Solely On ASP, MedPAC Says

Medicare Payment Advisory Committee unanimously recommends average sales price-based reimbursement for dialysis drugs in all settings. More timely updating of payment rates is cited as the main advantage of ASP-based reimbursement over reimbursement based on average acquisition payment.